Bioavailability of BMS-582949 Following Oral Administration of a 200 mg BMS-751324 (Pro-drug of BMS-582949) Tablet Relative to 2x100 mg BMS-751324 Capsules and to a 100 mg BMS-582949 Tablet, and the Effect of a High Fat Meal on the Bioavailability of BMS-582949 Following Oral Administration of a 200 mg BMS-751324 Tablet in Healthy Subjects.

Trial Profile

Bioavailability of BMS-582949 Following Oral Administration of a 200 mg BMS-751324 (Pro-drug of BMS-582949) Tablet Relative to 2x100 mg BMS-751324 Capsules and to a 100 mg BMS-582949 Tablet, and the Effect of a High Fat Meal on the Bioavailability of BMS-582949 Following Oral Administration of a 200 mg BMS-751324 Tablet in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2016

At a glance

  • Drugs BMS 582949 (Primary) ; BMS 751324 (Primary)
  • Indications Atherosclerosis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top